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ABSTRACT 
Objective: This study aimed to develop a microstructured lipid carrier that improves the rate of dissolution of the active pharmaceutical ingredient 
(API) Albendazole. 
Methods: A solvent diffusion method was used for the development of microstructured lipid carriers. The developed carriers were characterized by 
optical microscopy, infrared spectroscopy, differential scanning calorimetry (DSC), X-ray diffractometry (XRD), and dissolution testing. 
Results: The morphology of the carriers was irregular, and their size tends to decrease with the addition of modifiers. Furthermore, the 
diffractograms and the thermograms indicated a loss of crystallinity. The thermograms and infrared spectra showed that there are not chemical 
incompatibilities between the API and the excipients. When the lipid carrier particles were modified with Aerosil® 200 (specifically when using this 
excipient at a level of 6% w/w), dissolution was increased up to 85.96±1.17 % of the drug content as per USP test for Albendazole tablets in 
comparison with 36.13±0.52 % for a lipid carrier formulation without modifiers. 
Conclusion: It was demonstrated that it is possible to develop a modified lipid carrier that improves the dissolution rate of an API with a low 
solubility, which was related to the amorphization of the API crystalline structure.  
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INTRODUCTION 
Current methods of drug delivery aim to facilitate the arrival of the 
API to a specific therapeutic target. One of the main considerations 
for oral administration of drugs is to ensure the dissolution of the 
active pharmaceutical ingredients. To achieve this, it is possible to 
use drug delivery systems based on micro and nanotechnology. 
Within these systems, lipid carrier particles are becoming more 
popular, because this type of materials are easy to characterize and 
can be use in different administration routes [1].  
The use of lipid materials as a matrix for microspheres can have 
some advantages. For example, these kinds of materials are usually 
biocompatible, biodegradable, non-immunogenic, and they are not 
expensive [2]. One of their main advantages is that they allow to 
encapsulate a great variety of non-water soluble compounds [2-4]. 
Among these compounds, these carriers could be useful to the class 
II drugs according to the Biopharmaceutical Classification System, 
which are characterized by showing a low aqueous solubility and 
high membrane permeability. These characteristics cause a limited 
absorption due to a low dissolution rate [3]. An example of this kind 
of drug is Albendazole (ABZ), which has a low bioavailability that is 
attributed to its low aqueous solubility, which is considered the rate-
limiting step for its absorption [5]. 
This research aims to study the effect on the dissolution rate for ABZ 
from lipid carrier particles modified with different excipients, to favor 
the fast disintegration of the lipid matrix and the release of the API. 
Specifically, the incorporation of a pore-forming agent (Aerosil® 200), a 
disintegrant (crospovidone), and the combination of both were tested. 
Additionally, the improvement in the dissolution rate of ABZ would 
allow its application in different pathologies that need the drug to 
reach systemic circulation (for example neurocysticercosis). 
Currently, it is common to achieve an improvement in the dissolution 
rate of poorly soluble drugs through the formulation of complexes with 
cyclodextrins and solid dispersions, which can be costly and not as 
effective when developing in vivo trials. The advantages of formulating a 
lipid carrier are improving a drug´s dissolution and in vivo absorption, 
high biocompatibility, and its low cost compared to other microparticle 
manufacturing techniques. This type of lipid carriers could be tested in 
other pharmaceutical ingredients that need significant improvements in 
their dissolution rates.  
MATERIALS AND METHODS 
Chemicals and reagents 
The reagents used were hydrochloric acid, Aerosil® 200 (colloidal 
silica), ABZ, crospovidone, ethanol, sodium hydroxide, methanol, 
glyceryl monostearate, polyethylene glycol 6000 (PEG 6000), 
polyvinylpyrrolidone K25, and caprylic/capric triglyceride. 
Preparation of lipid carriers  
The solvent diffusion method for the formation of nanostructured 
lipid carriers, described by Hu et al., was followed with some 
modifications [6]. The API was dissolved in 25 ml of acidified 
methanol, then the glyceryl monostearate, the caprylic/capric 
triglyceride, and the polyethylene glycol 6000 (PEG 6000) were 
dissolved in the ABZ solution, with manual agitation, on a water bath 
at 55 °C. The resultant organic solution was rapidly dispersed into 
100 ml of 0.2% polyvinylpyrrolidone K25 w/v aqueous solution, 
under mechanical stirring at 600 rpm on a water bath at 55 °C for 3 
min. Then 300 ml of cold distilled water (5–10 °C) was added and 
the dispersion was transferred to an ice bath, maintaining the 
agitation. Stirring was stopped when the dispersion reached a 
temperature of about 20 °C. It was left to rest and then the 
supernatant liquid was decanted. The microparticles were placed on 
absorbent paper towels and were allowed to dry at room 
temperature for 24 h in a desiccator with silica. The modifying 
agents (Aerosil® 200 and/or crospovidone), were added in the 
organic solution at different proportions, following the same 
methodology described above. The exact composition of all carriers 
prepared is given in table 1. 
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Table 1: Formulations of the microstructured lipid carriers (%w/w) 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
PEG 6000 42.5 41.5 40.5 39.5 39.0 38.5 41.5 40.5 39.5 39.5 39.5 39.5 
Glyceryl monostearate 31.9 31.1 30.4 29.6 29.2 28.9 31.1 30.4 29.6 29.6 29.6 29.6 
Caprylic/capric triglyceride 10.6 10.4 10.1 9.9 9.8 9.6 10.4 10.1 9.9 9.9 9.9 9.9 
ABZ 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 
Aerosil® 200 0.0 2.0 4.0 6.0 7.0 8.0 0.0 0.0 0.0 1.5 3.0 4.5 
Crospovidone 0.0 0.0 0.0 0.0 0.0 0.0 2.0 4.0 6.0 4.5 3.0 1.5 
ABZ: albendazole; PEG 6000: polyethylene glycol 6000  
 
Carrier’s characterization  
Morphology and size 
The shape and size of the lipid carriers were determined with an 
Olympus CX31 optical microscope, the samples were visualized with a 
magnification setting of 40X and were analyzed using ImageJ software. 
Differential scanning calorimetry (DSC) 
A Setline® STA/STA+calorimeter (Setaram) was employed. 
Approximately 10 mg of the samples were put in the aluminum sample 
holders. The scan rate was 10 °C/min in the 25 °C-250 °C temperature 
range. The analysis was developed under a helium purge and an empty 
aluminum sample holder was used as the reference. 
X-ray diffraction (XRD) 
We analyzed samples in a Bruker D8 Advanced powder X-ray 
diffractometer. The source used was Cu Kα1-Kα2, with Bragg 
Bentano configuration and Linx-eye linear detector. We collected the 
data in a 2θ range from 5 ° to 50 ° with 0.020 ° per step and a speed 
per step of 384 s. 
Fourier-transform infrared spectroscopy (FT-IR) 
We used a Perkin Elmer FT-IR spectrometer spectrum 1000 with 
potassium bromide disks and a lithium tantalate detector to collect 
FT-IR spectra, with a rate of 0.3 cm/s and a resolution of 4.0 cm-1, in 
intervals of 2.0 cm-1. All spectra were recorded from 4000 cm-1 to 
400 cm-1. 
Drug loading and encapsulation efficiency 
We followed the methodology for content uniformity described in 
the monograph of ABZ tablets in USP40 with some modifications [7]. 
We analyzed each formulation in triplicate. We transferred samples 
of microparticles equivalent to 40 mg of ABZ (according to the 
theoretical amount in the formulation) to 100 ml volumetric flasks. 
Then, we added about 60 ml of acidified methanol, and mechanically 
stirred the flasks for 30 min. Finally, we diluted the solutions with 
acidified methanol up to a volume of 100 ml. 
We filtered a portion of each solution, discarding the first 20 ml. Then, 
we transferred 1.0 ml of the filtrate to a 200 ml volumetric flask, and 
diluted it with 0.1 N sodium hydroxide up to a volume of 200 ml. We 
measured the absorbance of these solutions and the standard solution at 
the wavelength of maximum absorption, at approximately 308 nm. We 
used 0.1 N sodium hydroxide as the blank solution. 
Calculations were performed as follows:  
ABZ amount (mg) =
 20 �Concentration of ABZ standard solution �μg
ml




Drug loading (%) =  ABZ amount 
carriers weight (mg)
x 100 ……. (2) 
Encapsulation ef�iciency (%)  =  ABZ amount 
Theoretical drug quantity (mg)
x 100 … (3) 
Dissolution test 
We followed the methodology described in the monograph of ABZ 
tablets of USP40 [7]. The dissolution medium was 900 ml of 0.1 N 
hydrochloric acid at 37 °C±0.5 °C and dissolution apparatus 2 was 
used at 50 rpm for 30 min. We used samples of micro particles 
equivalent to 200 mg ABZ (based on the results of drug loading 
assay). To facilitate the incorporation and wetting of the lipid 
carriers with the dissolution medium, we mixed the dry particles 
with 3% w/w sodium lauryl sulfate for three minutes before adding 
them to the dissolution medium. We analyzed each formulation in 
triplicate.  
We transferred a volume of 10.0 ml of a filtered portion of the 
solution under test to a 250 ml volumetric flask, and then diluted it 
with 0.1 N sodium hydroxide to volume. We measured the 
absorbance of these solutions and the standard solution at the 
wavelength of maximum absorption, at approximately 308 nm, using 
0.1 N sodium hydroxide as the blank solution. 
Calculations were performed as follows:  
ABZ amount (mg) =
 22,5 �Concentration of ABZ standard solution �μg
ml




ABZ released (%) =  ABZ amount 
 200 mg
x 100 …… (5) 
Data analysis 
The data are expressed as mean ± SD and were compared by one-
way ANOVA, followed by Tukey post hoc test. The differences were 
considered statistically significant when p<0.05. The analysis was 
performed using the GraphPad Prism 5 software and Microsoft Excel 
2016. 
RESULTS AND DISCUSSION  
The particle size determination of the carriers is given in fig. 1. In 
general, it is noted that with the addition of Aerosil® 200 in 
concentrations above 4%, and in all the formulations with 
crospovidone or the combination of Aerosil® 200-crospovidone, a 
decrease in the maximum particle size of the carriers is obtained, 
in comparison with the formulation without modifying agents 
(F1). 
Aerosil® 200 has been reported as a viscosity-increasing agent [8, 9], 
which generates a decrease in the size of the microparticles [8].  
Regarding the effect of crospovidone, when we putted the 
disintegrants in contact with a suitable fluid, they swollen and 
increased their size. The absorption of the liquid leads to an 
increase in the effective concentration of the solutes and to a 
decrease in the volume of free fluid, which reduces the 
movement of the liquid and this generates the increase in 
viscosity [10]. 
Although we originally added both excipients in the organic phase, it 
should be considered that a certain amount could have passed to the 
aqueous phase. In that case, an increased viscosity has the effect of 
producing a higher degree of dispersion of the organic phase, 
forming smaller globules that after solvent diffusion and cooling will 
generate smaller solid microparticles.  
When we examined the morphology of these carriers, as shown in 
fig. 2, we found that they had irregular shapes and sizes. 
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Fig. 1: Size determination of the microstructured lipid carriers, data given in mean±SD; n= 15 
 
 
Fig. 2: Morphology of the microstructured lipid carriers. F1 (a), F4 (b), F8 (c) and F11 (d) 
 
 
Fig. 3: Thermograms of the carriers developed. In descending order: albendazole (ABZ), F1, F4, F8 and F11 
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The thermograms obtained for the carriers developed are shown in 
fig. 3. There are two endothermic transitions, the first is between 60-
70 °C and the second is a broad and slightly pronounced peak before 
200 °C. The first transition is related to the melting of the matrix and 
the second transition is related to the melting of the API. However it 
is noted that the peak does not have the same characteristics as the 
peak registered for pure ABZ. The absence of the endothermic peak 
of the API can be attributed to the dissolution of the API in the 
molten matrix [11, 12], or the loss of crystallinity of the drug, i.e. it 
becomes an amorphous solid [12, 13]. We can assume a change in 
the crystalline structure of the compound, since the fusion occurs at 
a lower temperature and the peak is wider and less intense than that 
corresponding to the pure drug [9]. 
Diffractograms from the XRD assay are shown in fig. 4. The carriers 
designed clearly show the presence of the signals assigned to the 
API, which indicates the absence of chemical interactions between 
the components. However, these characteristic transitions of the API 




Fig. 4: X-ray diffractograms of Albendazole (ABZ) (a), F1 (b), F4 (c), F8 (d) and F11 (e) 
 
The IR spectra of ABZ and the carriers are shown in fig. 5. The 
main API-related signals show no changes in the carriers’ spectra, 
which indicates that there are no chemical interactions between 
the API and the excipients. It can be seen that the absorption band 
at 3324 cm-1 in the carriers spectra becomes a little wider than in 
the original spectrum of ABZ, which is attributed to the stretching 
vibrations of the O-H bond presents in glyceryl monostearate and 
PEG 6000 [15, 16]. Another difference found in the carriers’ 
spectra consists of two intense peaks present approximately at 
2915 cm-1 and 2849 cm-1, which represent C-H bond stretches of 
the excipients. The signal corresponding to the ABZ ester appears 
at 1740 cm-1, which is due to the stretching vibrations of the C = O 
bonds of glyceryl monostearate and Caprylic/capric triglyceride 
[16, 17]. 
 
a)                                                                       b)                 
c)                                                                      d)                 
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Fig. 5: FT-IR spectra of Albendazole (ABZ) (a), F1 (b), F4 (c), F8 (d) and F11 (e) 
 
Table 2 shows the results of the assays related to drug loading, 
encapsulation efficiency, and dissolution test. Regarding the 
dissolution test, in general, it is evident that the incorporation of the 
modifying agents increases the amount of dissolved ABZ, being the 
Aerosil® 200 at a concentration of 6% the excipient that improves 
the dissolution of the API at greater extent. 
 
Table 2: Drug loading, encapsulation efficiency and dissolution test 
Formulation Drug loading (%) Encapsulation efficiency (%) Dissolution percentage (mean±SD) 
ABZ - - 1.50±0.50 
ABZ+surfactant - - 11.45±3.21 
F1 27.40±0.67 80.24±1.96 36.13±0.52 
F2 27.11±0.79 75.13±2.17 19.94±0.23 
F3 24.53±0.75 76.38±2.35 59.64±1.23 
F4 21.17±0.48 76.79±1.74 85.96±1.17 * 
F5 18.83±1.27 75.15±5.07 76.87±0.33 
F6 26.76±0.50 82.92±1.54 69.54±1.91 
F7 24.63±0.12 72.63±0.35 27.47±0.71 
F8 26.25±0.23 77.98±0.69 57.77±0.43 
F9 25.41±0.39 78.58±1.20 55.77±0.73 
F10 25.70±0.49 86.59±1.64 64.03±0.69 
F11 27.50±0.32 89.46±1.06 67.54±0.15 
F12 23.74±0.42 85.80±1.48 67.74±0.88 
Data given in mean±SD, ABZ: albendazole. n=3 * p<0.05 when comparing all groups.  
a)                                                                                       b) 
                                          c)                                                                                            d) 
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The incorporation of a liquid lipid in the solid matrix causes that the 
microstructure of the carriers becomes imperfect. In this case, this 
facilitates the release of the drug from the matrix [6]. During the 
cooling process, the solid lipid crystallize forming a small nucleus 
free of liquid lipid. Therefore, most of the caprylic/capric 
triglyceride is going to be located in the outer layer of the carriers. 
As the drug tends to be more soluble in the liquid lipid, this outer 
layer has a higher drug load that can be easily released by diffusion 
or erosion of the matrix [17]. 
It is important to mention that the incorporation of PEG 6000 into 
the lipid carriers has an important role in the release of the API. 
When the carriers are exposed to the dissolution medium, the PEG 
begins to dissolve, which favors the degradation of the matrix, 
increasing its porosity and facilitating the diffusion of ABZ into the 
dissolution medium [18]. 
Aerosil® 200 can reduce the size and agglomeration of the particles, 
which increases the surface area, leading to an increase in the 
interaction of the carriers with the dissolution medium, favoring the 
diffusion of the drug to the medium [19]. Besides, it should be taken 
into account that the Aerosil® 200 is hydrophilic and it will tend to 
hydrate [20]. Therefore, being dispersed in the carrier matrix, it will 
facilitate its hydration, increasing the contact of the carrier with the 
dissolution medium, and promoting the diffusion of the API.  
The mechanism of drug release from our carriers can occur by 
diffusion and/or erosion of the matrix [17]. The mechanism of 
disintegration of crospovidone is related to swelling, porosity, and 
capillarity [21-23]. It could be thought that by obtaining lipid 
carriers with crospovidone dispersed in its structure, it would 
behave similarly. Upon contact with the dissolution medium, 
crospovidone will swell, producing the erosion of the matrix and 
entry of liquid into the carriers, which would explain the 
improvement observed in the dissolution of the API.  
Besides the technological benefits provided by the designed carriers, 
such as the greater surface contact with the dissolution medium and 
rapid release of the drug from the matrix, the modification of 
crystalline structure should be considered as a determining 
characteristic. Many solid compounds can present polymorphism, 
due to their ability to form crystalline networks with different 
arrangements or conformations. The polymorphs of the same 
chemical compound, in addition to differing in the structure of their 
solid-state, they also differ in physical and chemical properties, 
which affects the stability, dissolution, bioavailability, and other 
characteristics of the drug [24]. In general, it is established that a 
solid in an amorphous state is easier to dissolve than the same 
compound on a state with an ordered crystalline lattice, since less 
energy is needed to distort its molecular network. The DSC and XRD 
assays showed a loss in the crystallinity of the API in the carriers 
developed, which is correlated with the improvements observed in 
the dissolution test. 
CONCLUSION 
The lipid carriers modified with Aerosil® 200 (specifically when 
using the excipient at 6% w/w), show the best results regarding the 
performance in the dissolution test. 
The improvement in the drug release rate of ABZ can be attributed 
to the decrease in the crystallinity of the active ingredient in the 
formulations, as suggested by DSC and XRD assays. 
From the infrared spectra and XRD of the lipid particulate carriers, 
where characteristic signals of the API are present, we can conclude that 
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